BACCI, Sabrina and Nathalie NICOLAY. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update. FNUSA, ECDC, 2022.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update
Authors BACCI, Sabrina and Nathalie NICOLAY.
Edition 2022.
Publisher FNUSA, ECDC
Other information
Original language English
Type of outcome Research and development projects
Field of Study 30230 Other clinical medicine subjects
Country of publisher Sweden
Confidentiality degree is not subject to a state or trade secret
WWW COVID-19
RIV identification code RIV/00216224:14110/22:00127692
Organization unit Faculty of Medicine
Keywords (in Czech) Technical Report; COVID-19; SARI
Keywords in English Technical Report; COVID-19; SARI
Tags ECDC, FNUSA, user
Tags International impact
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 5/4/2023 13:32.
Abstract
This current report builds on previous analyses [3,4,5] and extends the age groups included. An overview of outcomes, study period and age groups included in the analysis are presented in Table 1 Previous ECDC publications on COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, are available [3,4]. This third update contains vaccine effectiveness results among individuals aged 20 years and older for the Omicron period) for the first time as well as estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria).
Links
90128, large research infrastructuresName: CZECRIN III
PrintDisplayed: 17/5/2024 18:27